Advanced pharmaceutical solutions
Targeted • Precise • Effective
A Single-Source CDMO Partner Accelerating Your Antibody Drug Conjugate from Concept to Commercial Supply
Antibody Drug Conjugates demand a rare combination of expertise — complex small-molecule chemistry, biologics development, high-potency containment, and tightly controlled conjugation processes. Most ADC programs lose time and capital coordinating these capabilities across multiple vendors.
At Shilpa Biologics and Shilpa Pharma Lifesciences, we eliminate that fragmentation. Our fully integrated ADC platform brings payloads, linkers, antibodies, conjugation, analytical characterization, and GMP manufacturing into a single, accountable partnership — so your molecule moves faster, with fewer hand-offs, and with global regulatory readiness built in.
Rigorous QbD-driven development ensuring scalable and reproducible processes
Consistent DAR control and reduced heterogeneity across Lysine and Cysteine platforms
Deep synthetic chemistry expertise with a broad portfolio of cytotoxic payloads
Comprehensive analytics from DAR determination to disulfide mapping
Purpose-built isolator-based facilities for highly potent ADC production
Sterile fill-finish and lyophilization cycle development under aseptic conditions
Structured tech transfer protocols with full documentation support
From pilot to commercial scale with regulatory-ready validation packages
Discovery Support
Early-stage candidate evaluation and feasibility
Preclinical Development
Non-GMP to GMP transition with full analytics
Clinical Manufacturing
Phase I–III supply with regulatory documentation
Commercial Supply
Validated, scalable processes for market launch
